Catherine Lai

Dr. Catherine Lai from UPenn discusses AML treatment options, including chemotherapy regimens based on core binding factors, variations in toxicity, and advancements like Gemtuzumab. She also explores recovery strategies, repeatable marrow biopsies, and different treatment approaches based on risk categories and patient fitness levels. The podcast ends with key takeaways on AML diagnosis criteria, induction regimens, specific treatment options for mutations, and the importance of seeking feedback.

Dr. Catherine Lai discusses AML classification, genetic mutations, and risk factors. Topics include treatment-related factors, hereditary myeloid malignancies, and managing leukostasis and tumor lysis syndrome in leukemia.